Incorporation of uncertainty in health economic modelling studies

PharmacoEconomics

Volumn 23, Issue 6, 2005, Pages 529-536

  O'Hagan, Anthony ^a   McCabe, Christopher ^a   Akehurst, Ron ^a   Brennan, Alan ^a   Briggs, Andrew ^b   Claxton, Karl ^c   Fenwick, Elisabeth ^c   Fryback, Dennis ^d   Sculpher, Mark ^c   Spiegelhalter, David ^e   Willan, Andrew ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT;

ANALYTICAL ERROR; BAYES THEOREM; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFECT; FREQUENCY ANALYSIS; HUMAN; HYPOTHESIS; MEDICAL DECISION MAKING; MEDICAL ETHICS; MODEL; MONTE CARLO METHOD; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL DISTRIBUTION; TREATMENT INDICATION; TREATMENT OUTCOME; VARIANCE;

ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS, PHARMACEUTICAL; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; PARKINSON DISEASE; UNCERTAINTY;

EID: 22244435962     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523060-00001     Document Type: Review

References (33)

1. Nuijten MJC. Incorporation of statistical uncertainty in health economic modelling studies using second order Monte Carlo simulations. Pharmacoeconomics 2004; 22 (12): 759-69
2. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: OHE/Oxford University Press, 2001: 172-214
3. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice in decision analytic modelling in health care evaluation: report of the ISPOR Task Force on good research practices: modelling studies. Value Health 2003; 6 (1): 9-17
4. Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: OHE/Oxford University Press, 2001
5. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost effectiveness analysis. In: Gold MR, Siegal JE, Russell LB, et al., editors. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996: 247-75
6. Drummond MG, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997: 232-64
7. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost effectiveness analysis. In: Gold MR, Siegal JE, Russell LB, et al., editors. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996: 247-75
8. National Institute for Clinical Excellence. Guide to the methods of health technology appraisal. London: NICE, 2004 Apr
9. Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects, and C/E ratios alongside a clinical trial. Health Econ 1994; 3 (5): 309-19
10. Luce B, O'Hagan A. A primer on Bayesian statistics in health economics and outcomes research. London: MEDTAP International, 2003
11. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002; 360: 711-5
12. Akehurst RL, Anderson P, Brazier JE, et al. Decision analytic modelling in economic evaluation of health technologies. Pharmacoeconomics 2000; 17 (5): 443-4
13. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost effectiveness models: a suggested frame-work and example of application. Pharmacoeconomics 2000; 17 (5): 461-77
14. Briggs A. Handling uncertainty in cost effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
15. McCabe C, Dixon S. Testing the validity of cost effectiveness models. Pharmacoeconomics 2000; 17 (5): 501-13
16. Parmigiani G. Modeling in medical decision making: a Bayesian approach. Chichester: John Wiley and Sons, 2002
17. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modelling in conjunction with individual patient simulation modelling: a case study describing the calculation of cost-effectiveness ratios for the treatment of osteoporosis. Med Decis Making 2004; 24 (1): 89-100
18. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003; 326: 522-6
19. Cooper NJ, Sutton AJ, Mugford M, et al. Use of Bayesian Markov Chain Monte Carlo methods to model cost data. Med Decis Making 2003; 23: 38-53
20. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22 (4): 290-308
21. Spiegelhalter DJ, Abrams KR, Miles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley & Sons, 2003
22. Stinnett A, Paltiel A. Estimating CE ratios under second order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997; 17: 483-9
23. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta-interferon and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004; 8 (27): 1-78
24. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157-77
25. Briggs AH, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7 (8): 723-40
26. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-89
27. Ades AE, Lu G, Claxton K. Expected value of sample information in medical decision modelling. Med Decis Making 2004; 24 (2): 702-28
28. Tarn TYH, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10 (4): 5-15
29. Stinnett AA, Mullahy J. Net Health Benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making 1998; 18 (2): S65-80
30. Centre for Bayesian Statistics in Health Economics. Probabilistic sensitivity analysis in cost effectiveness modelling: part 1 [online]. Available from URL: http://www.shef.ac.uk/chebs/ [Accessed 2005 May 4]
31. Centre for Health Economics/Institute for Health Economics. Oxford-York advanced modelling methods for economic evaluation [online]. Available from URL: http://www.york.ac.uk/inst/che/modelling.htm [Accessed 2005 May 4]
32. Treeage Software Inc. Treeage software training healthcare advanced [online]. Available from URL: http://server.tree age.com/treeagepro/training/ advanced.asp [Accessed 2005 May 4]
33. Harvard Centre for Risk Analysis. Cost effectiveness analysis for medical technologies and pharmaceuticals [online]. Available from URL: http://www.hsph.harvard.edu/ccpe/programs/CEA.shtml [Accessed 2005 May 4]